

Claim 50. (Twice Amended) A pharmaceutically acceptable salt of claim 69 which is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

Claim 51. (Twice Amended) A pharmaceutically acceptable salt of claim 70 which is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

Claim 52. (Twice Amended) A pharmaceutically acceptable salt of claim 71 which is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal

cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

Claim 53. (Twice Amended) A pharmaceutically acceptable salt of claim 72 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

Claim 54. (Twice Amended) A pharmaceutically acceptable salt of claim 73 which is

a) a basic salt of organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

68. (Amended) A pharmaceutically acceptable salt of a compound which is:

*N*-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-

pyridyloxy)phenyl) urea,

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl)

urea,

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-

pyridyloxy)phenyl) urea; or

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-

pyridyloxy)phenyl) urea.

69. A pharmaceutically acceptable salt of the compound

*N*-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-

methylcarbamoyl)phenoxy)phenyl) urea.

70. A pharmaceutically acceptable salt of the compound

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-

pyridyloxy)phenyl) urea.

71. A pharmaceutically acceptable salt of the compound

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

72. A pharmaceutically acceptable salt of the compound

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl)

urea.

73. A pharmaceutically acceptable salt of the compound

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-

pyridyloxy)phenyl) urea.

74. (Amended) A method for the treatment of a cancerous cell growth mediated by raf kinase comprising administering a pharmaceutically acceptable salt of:

*N*-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-

methylcarbamoyl)phenoxy)phenyl) urea,

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea; or

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

75. (Amended) A method for the treatment of a cancerous cell growth as in claim 74 comprising administering a pharmaceutically acceptable salt of

*N*-(5-tert-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea.

76. (Amended) A method for the treatment of a cancerous cell growth as in claim 74 comprising administering a pharmaceutically acceptable salt of

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

77. (Amended) A method for the treatment of a cancerous cell growth as in claim 74 comprising administering a pharmaceutically acceptable salt of

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

78. (Amended) A method for the treatment of a cancerous cell growth as in claim 74 comprising administering a pharmaceutically acceptable salt of

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

79. (Amended) A method for the treatment of a cancerous cell growth as in claim 74

comprising administering a pharmaceutically acceptable salt of

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

80. A method as in claim 74 for the treatment of solid cancers.
81. A method as in claim 74 for the treatment of carcinomas, myleoid disorders or adenomas.
82. A method as in claim 75 for the treatment of carcinomas, myleoid disorders or adenomas.
83. A method as in claim 76 for the treatment of carcinomas, myleoid disorders or adenomas.
84. A method as in claim 77 for the treatment of carcinomas, myleoid disorders or adenomas.
85. A method as in claim 78 for the treatment of carcinomas, myleoid disorders or adenomas.
86. A method as in claim 79 for the treatment of carcinomas, myleoid disorders or adenomas.
87. A method as in claim 74 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
88. A method as in claim 75 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
89. A method as in claim 76 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
90. A method as in claim 77 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

91. A method as in claim 78 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

92. A method as in claim 79 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

93. A method as in claim 74 for the treatment of myeloid leukemia or villous colon adenomas.

94. A method as in claim 75 for the treatment of myeloid leukemia or villous colon adenomas.

95. A method as in claim 76 for the treatment of myeloid leukemia or villous colon adenomas.

96. A method as in claim 77 for the treatment of myeloid leukemia or villous colon adenomas.

97. A method as in claim 78 for the treatment of myeloid leukemia or villous colon adenomas.

98. A method as in claim 79 for the treatment of myeloid leukemia or villous colon adenomas.

99. (Amended) A method as in claim 74 wherein the pharmaceutically acceptable salt is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid,

benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

100. (Amended) A method as in claim 75 wherein the pharmaceutically acceptable salt administered is the tosylate salt of

*N*-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methyl carbamoyl)phenoxy)phenyl) urea.

101. (Amended) A method as in claim 76 wherein the pharmaceutically acceptable salt administered is the tosylate salt of

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

102. (Amended) A method as in claim 77 wherein the pharmaceutically acceptable salt administered is the tosylate salt of

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

103. (Amended) A method as in claim 78 wherein the pharmaceutically acceptable salt administered is the tosylate salt of

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

104. (Amended) A method as in claim 79 wherein the pharmaceutically acceptable salt administered is the tosylate salt of

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

105. (Amended) A pharmaceutically acceptable salt as in claim 69 which is the

tosylate salt of

*N*-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea.

106. (Amended) A pharmaceutically acceptable salt as in claim 70 which is the tosylate salt of

*N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

107. (Amended) A pharmaceutically acceptable salt as in claim 71 which is the tosylate salt of

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

108. (Amended) A pharmaceutically acceptable salt as in claim 72 which is the tosylate salt of

*N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

109. (Amended) A pharmaceutically acceptable salt as in claim 73 which is the tosylate salt of

*N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.